Marengo Therapeutics Inc. has entered into a multiyear research collaboration in oncology and autoimmune diseases with University of Pennsylvania Perelman School of Medicine. The research collaboration will provide deeper insights into the mechanism of action of Marengo’s selective dual T-cell agonists in oncology.
Axcynsis Therapeutics Pte Ltd. has described antibody-drug conjugates comprising an antibody or antigen-binding fragment targeting alkaline phosphatase placental type (ALPP) and/or alkaline phosphatase, germ cell type (ALPPL2) covalently linked to a cytotoxic agent through a linker reported to be useful for the treatment of cancer.
Allogenica SAS has been awarded a €2.5 million (US$2.7 million) grant under the French government’s France 2030 program to help advance its universal CAR T candidate, XL-001, for CD19-positive hematologic cancers.
Ampersand Biomedicines Inc. has secured $65 million in series B funding from investors including Ampersand’s founder, Flagship Pioneering, to support advancement of two lead programs and a new discovery partnership in obesity.
Shanghai Allist Pharmaceuticals Co. Ltd. has described phosphatidylinositol 3-kinase α (PI3Kα, H1047R mutant) allosteric inhibitors reported to be useful for the treatment of cancer.
Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized serine/threonine-protein kinase ULK1 inhibitors reported to be useful for the treatment of cancer, lymphangioleiomyomatosis and tuberous sclerosis.
RSS
